Published in Gut on July 01, 2005
Upper GI tract lesions in familial adenomatous polyposis (FAP): enrichment of pyloric gland adenomas and other gastric and duodenal neoplasms. Am J Surg Pathol (2014) 1.09
Treatment for superficial non-ampullary duodenal epithelial tumors. World J Gastroenterol (2014) 1.02
Prevalence of gastric and duodenal polyps and risk factors for duodenal neoplasm in korean patients with familial adenomatous polyposis. Gut Liver (2011) 0.91
The genetic basis of familial adenomatous polyposis and its implications for clinical practice and risk management. Appl Clin Genet (2015) 0.89
Extracolonic manifestations of hereditary colorectal cancer syndromes. Clin Colon Rectal Surg (2008) 0.85
Diagnosis, surveillance, and treatment strategies for familial adenomatous polyposis: rationale and update. Eur J Gastroenterol Hepatol (2014) 0.83
Recurrences are common after endoscopic ampullectomy for adenoma in the familial adenomatous polyposis (FAP) syndrome. Surg Endosc (2014) 0.80
Identification of patients at risk for hereditary colorectal cancer. Clin Colon Rectal Surg (2012) 0.79
Progression of duodenal adenomatosis in familial adenomatous polyposis: due to ageing of subjects and advances in technology. Fam Cancer (2011) 0.78
Hereditary Colorectal Cancer: Genetics and Screening. Surg Clin North Am (2015) 0.77
Duodenal adenoma surveillance in patients with familial adenomatous polyposis. World J Gastrointest Endosc (2015) 0.77
Advanced duodenal disease in familial adenomatous polyposis: how frequently should patients be followed up after successful therapy? Fam Cancer (2012) 0.76
Cost-effectiveness of prophylactic surgery for duodenal cancer in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev (2009) 0.75
Hepatocelluar carcinoma associated with attenuated familial adenomatous polyposis: a case report and review of the literature. Clin Colorectal Cancer (2011) 0.75
Loss of intestinal O-glycans promotes spontaneous duodenal tumors. Am J Physiol Gastrointest Liver Physiol (2016) 0.75
Emerging role of narrow band imaging in duodenum. World J Gastrointest Endosc (2015) 0.75
Lower gastrointestinal tract cancer predisposition syndromes. Hematol Oncol Clin North Am (2010) 0.75
Nonampullary duodenal adenoma: Current understanding of its diagnosis, pathogenesis, and clinical management. World J Gastroenterol (2016) 0.75
Gastric and duodenal polyps in familial adenomatous polyposis patients: Conventional endoscopy vs virtual chromoendoscopy (fujinon intelligent color enhancement) in dysplasia evaluation. World J Clin Oncol (2017) 0.75
Surveillance using capsule endoscopy is safe in post-colectomy patients with familial adenomatous polyposis: a prospective Japanese study. Fam Cancer (2016) 0.75
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 7.25
Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A (1997) 7.07
APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer (2001) 4.54
Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell (1998) 4.22
Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet (1989) 3.84
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res (1998) 3.79
The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology (1992) 3.59
Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem (1997) 3.55
Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol (1996) 2.87
Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology (2001) 2.85
The mechanism of action of aspirin. Thromb Res (2003) 2.72
Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg (1993) 2.70
Duodenal adenomatosis in familial adenomatous polyposis. Gut (2004) 2.38
Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol (2001) 2.38
Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol (2004) 2.31
Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci U S A (2000) 2.23
Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet (1998) 2.12
Argon plasma coagulation in flexible gastrointestinal endoscopy: pilot experiences. Endoscopy (1997) 2.10
Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res (2000) 2.00
Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res (2002) 2.00
Sulindac for polyposis of the colon. Am J Surg (1989) 1.95
Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut (1997) 1.88
Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology (2000) 1.84
Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut (2002) 1.81
The impact of familial adenomatous polyposis on the tumorigenesis and mortality at the several organs. Its rational treatment. Ann Surg (1993) 1.76
Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol (2003) 1.69
Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy (1999) 1.63
Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut (2001) 1.63
The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc (1999) 1.55
Gene expression profiling of tumor-stromal interactions between pancreatic cancer cells and stromal fibroblasts. Cancer Res (2004) 1.54
Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J Exp Med (1999) 1.48
Lipoxygenase modulation to reverse carcinogenesis. Cancer Res (2001) 1.46
Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polyposis. J Clin Invest (2000) 1.44
Development of duodenal cancer in a patient with familial adenomatous polyposis. J Gastroenterol (2000) 1.41
Malignant neoplasms of the duodenum. Surg Gynecol Obstet (1980) 1.39
Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc (2002) 1.37
Surgical polypectomy of duodenal adenomas in familial adenomatous polyposis: experience of two European centres. Br J Surg (1993) 1.32
The relationship between frequencies of extracolonic manifestations and the position of APC germline mutation in patients with familial adenomatous polyposis. Jpn J Clin Oncol (2000) 1.32
Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial adenomatous polyposis. The Leeds Castle Polyposis Group (Upper Gastrointestinal Committee). J Clin Pathol (1994) 1.29
The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur J Cancer (2000) 1.28
Effect of sulindac on small polyps in familial adenomatous polyposis. Lancet (1995) 1.25
Mutation cluster region, association between germline and somatic mutations and genotype-phenotype correlation in upper gastrointestinal familial adenomatous polyposis. Am J Pathol (2002) 1.22
Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases. Dis Colon Rectum (1992) 1.12
Pancreas-sparing duodenectomy: indications, surgical technique, and results. Surgery (1995) 1.12
Villous tumors of the duodenum: reappraisal of local vs. extended resection. J Gastrointest Surg (2000) 1.09
Cyclooxygenase-2 and gastric carcinogenesis. APMIS (2003) 1.06
Administration of an unconjugated bile acid increases duodenal tumors in a murine model of familial adenomatous polyposis. Carcinogenesis (1999) 1.05
Surgical treatment of severe duodenal polyposis in familial adenomatous polyposis. Br J Surg (1998) 1.05
Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells. Cancer Res (2001) 1.05
Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol (2004) 1.04
Causes of death in familial adenomatous polyposis. Scand J Gastroenterol (1999) 1.03
Review article: genetic testing and counselling for hereditary colorectal cancer. Aliment Pharmacol Ther (2002) 1.01
Photodynamic therapy for polyps in familial adenomatous polyposis--a pilot study. Eur J Cancer (1995) 1.00
Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis. Br J Surg (2003) 0.98
Genetic predisposition to clinical manifestations in familial adenomatous polyposis with special reference to duodenal lesions. Am J Gastroenterol (2002) 0.97
The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis. Gastrointest Endosc (2002) 0.96
Prospective randomized study of sulindac versus calcium and calciferol for upper gastrointestinal polyps in familial adenomatous polyposis. Br J Surg (1996) 0.96
Slow progression of periampullary neoplasia in familial adenomatous polyposis. J Gastrointest Surg (2002) 0.95
Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum (1997) 0.95
Endoscopic surveillance and ablative therapy for periampullary adenomas. Am J Gastroenterol (2001) 0.94
Clinical characteristics of familial adenomatous polyposis and management of duodenal adenomas. J Gastrointest Surg (2004) 0.94
Long-term follow-up of patients with familial adenomatous polyposis undergoing pancreaticoduodenal surgery. J Gastrointest Surg (2002) 0.93
Interstitial cell cyclooxygenase-2 expression is associated with increased angiogenesis in human sporadic colorectal adenomas. J Pathol (2002) 0.89
Sulindac for periampullary polyps in FAP patients. Int J Colorectal Dis (1997) 0.89
Photodynamic therapy for malignant tumours of the ampulla of Vater. Gut (1995) 0.89
Attenuated familial adenomatous polyposis presenting as ampullary adenocarcinoma. Gut (2003) 0.87
Management of advanced duodenal polyposis in familial adenomatous polyposis. J Gastrointest Surg (2006) 0.87
Extracolonic polyps in familial polyposis coli and Gardner's syndrome. Dis Colon Rectum (1985) 0.87
Endoscopic snare papillectomy in patients with familial adenomatous polyposis and ampullary adenoma. Endoscopy (1997) 0.87
Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. J Gastrointest Surg (2002) 0.86
Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways. Clin Cancer Res (2000) 0.86
Familial adenomatous polyposis: efficacy of endoscopic and surgical treatment for advanced duodenal adenomas. Dis Colon Rectum (1999) 0.86
Overexpression of p53 in duodenal tumours in patients with familial adenomatous polyposis. Br J Surg (1996) 0.85
Photodynamic therapy for villous adenomas of the colon and rectum. Endoscopy (1994) 0.84
Gardner syndrome and periampullary malignancy. Am J Med Genet (1980) 0.82
Enhanced cyclooxygenase-2 expression in sporadic and familial adenomatous polyposis of the human colon. Scand J Gastroenterol (2001) 0.81
Malignant change in a duodenal adenoma in familial adenomatous polyposis: report of a case. Am J Gastroenterol (1998) 0.80
Nonpolypoid adenomas of the duodenum in patients with familial adenomatous polyposis (Gardner's syndrome). Gastrointest Endosc (1996) 0.80
Disappearance of duodenal polyps in Gardner's syndrome with sulindac therapy. Am J Gastroenterol (1993) 0.79
p53 and K-ras status in duodenal adenomas in familial adenomatous polyposis. Br J Surg (1997) 0.79
Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis. Dis Colon Rectum (2001) 0.78
Pancreatico-duodenectomy for cancer and precancer in familial adenomatous polyposis. Int J Colorectal Dis (1993) 0.76
Growth factor expression and proliferation kinetics in periampullary neoplasms in familial adenomatous polyposis. Cancer (1995) 0.76
Progressive duodenal adenomatosis in a familial adenomatous polyposis pedigree with APC mutation at codon 1556. Dis Colon Rectum (2002) 0.76
Adenomas of the ampulla of vater in familial adenomatous polyposis: Christian Theodore responds. Gastroenterology (2004) 0.76
Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology (1997) 9.70
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet (1997) 4.86
Progression model for pancreatic cancer. Clin Cancer Res (2000) 4.60
Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med (1987) 4.55
Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res (1997) 4.54
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res (2001) 4.19
Molecular diagnosis of familial adenomatous polyposis. N Engl J Med (1993) 4.07
Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am J Clin Nutr (1997) 3.75
The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology (1992) 3.59
Lymphocytic ("microscopic") colitis: a comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol (1989) 3.02
The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res (2001) 3.02
Collagenous colitis with mucosal tears on endoscopic insufflation: a unique presentation. Gut (2002) 2.81
Inhibition of apoptosis during development of colorectal cancer. Cancer Res (1995) 2.77
Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol (1999) 2.59
Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res (2001) 2.50
Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res (2000) 2.40
Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter (1996) 2.26
Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. Cancer Res (1998) 2.23
The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet (2004) 2.10
Desmoid tumours in familial adenomatous polyposis. Gut (1994) 2.08
Surgical treatment of pancreatic adenocarcinoma; actual survival and prognostic factors in 343 patients. Eur J Cancer (2004) 2.00
Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res (2001) 1.98
Chronic colitis with thickening of the subepithelial collagen layer (collagenous colitis): histopathologic findings in 15 patients. Hum Pathol (1987) 1.97
Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. Gut (2010) 1.94
STK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreas. Am J Pathol (2001) 1.89
Nature meets nurture: molecular genetics of gastric cancer. Hum Genet (2009) 1.87
Phenotypic and molecular characteristics of hyperplastic polyposis. Gastroenterology (2000) 1.86
The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology (1995) 1.86
Variable phenotype of familial adenomatous polyposis in pedigrees with 3' mutation in the APC gene. Gut (1998) 1.85
Prevalence and importance of pigmented ocular fundus lesions in Gardner's syndrome. N Engl J Med (1987) 1.76
Goblet cell carcinoid of the appendix: a specific type of carcinoma. Histopathology (2007) 1.73
Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res (1998) 1.73
Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res (1998) 1.71
Decreased expression of the gut-enriched Krüppel-like factor gene in intestinal adenomas of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous polyposis patients. FEBS Lett (2000) 1.70
Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol (2000) 1.69
Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology (1997) 1.67
Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol (2011) 1.63
Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol (2001) 1.61
Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut (1999) 1.59
Molecular pathology of pancreatic cancer. Cancer J (2001) 1.56
Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer (2004) 1.54
Familial pancreatic cancer. Cancer J (2001) 1.51
Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol (2000) 1.44
Mucosal prolapse in the pathogenesis of Peutz-Jeghers polyposis. Gut (2006) 1.42
Large genomic deletions of SMAD4, BMPR1A and PTEN in juvenile polyposis. Gut (2008) 1.41
A filing system for the gastroenterology/hepatology consultant. Am J Gastroenterol (1995) 1.39
Geographical variance in the risk of gastric stump cancer: no increased risk in Japan? Jpn J Cancer Res (1991) 1.39
Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study. Am J Gastroenterol (2011) 1.36
Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol (2002) 1.34
Role of neuronal nicotinic receptors in the effects of nicotine and ethanol on contextual fear conditioning. Neuroscience (2004) 1.33
Familial pancreatic cancer. Ann Oncol (1999) 1.33
Collagenous colitis: physiologic and histopathologic studies in seven patients. Ann Intern Med (1987) 1.32
Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology (1997) 1.31
Helicobacter pylori reinfection is virtually absent after successful eradication. J Infect Dis (1997) 1.27
Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res (1998) 1.23
The value of immunohistochemistry for collagen IV expression in colorectal carcinomas. Cancer (1991) 1.22
Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res (2001) 1.22
Pigmented ocular fundus lesions in the inherited gastrointestinal polyposis syndromes and in hereditary nonpolyposis colorectal cancer. Ophthalmology (1988) 1.21
Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro Surveill (2009) 1.20
Effect of polyamine depletion on c-myc expression in human colon carcinoma cells. J Biol Chem (1988) 1.19
[Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces]. Ned Tijdschr Geneeskd (2008) 1.18
Aberrant methylation of the Human Hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Biol Ther (2005) 1.18
Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am (1996) 1.18
Tumor-suppressor genes in pancreatic cancer. J Hepatobiliary Pancreat Surg (1998) 1.17
Genetic testing and counseling for hereditary forms of colorectal cancer. Cancer (1999) 1.16
Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer (2003) 1.16
Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions. Cancer Res (1990) 1.14
Microsatellite instability and expression of hMLH-1 and hMSH-2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res (2000) 1.12
Pathology of incipient pancreatic cancer. Ann Oncol (1999) 1.10
Pitfalls in the diagnosis of collagenous colitis: experience with 75 cases from a registry of collagenous colitis at the Johns Hopkins Hospital. Hum Pathol (1990) 1.09
Lymphocytic enterocolitis in patients with 'refractory sprue'. JAMA (1989) 1.09
Surgical management of neoplasms of the ampulla of Vater: local resection or pancreatoduodenectomy and prognostic factors for survival. Surgery (2004) 1.09
Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis. Prostaglandins Other Lipid Mediat (2000) 1.08
High resolution endoscopy and the additional value of chromoendoscopy in the evaluation of duodenal adenomatosis in patients with familial adenomatous polyposis. Endoscopy (2009) 1.07
Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol (2006) 1.06
Café-au-lait spots and early onset colorectal neoplasia: a variant of HNPCC? Fam Cancer (2001) 1.06
Evaluation of endoscopy for early detection of gastric-stump cancer. Lancet (1992) 1.06
Cancer of the esophagus and gastric cardia: recent advances. Dis Esophagus (2004) 1.06
Multivariate analysis of the risk of stomach cancer after ulcer surgery in an Amsterdam cohort of postgastrectomy patients. Am J Epidemiol (1991) 1.06
Cancer risk in collagenous colitis. Inflamm Bowel Dis (1999) 1.05
Oral and maxillofacial manifestations of familial adenomatous polyposis. Oral Dis (2007) 1.05
Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J Clin Pathol (2004) 1.04
The use of intraoral dexamethasone after extraction of mandibular third molars. Oral Surg Oral Med Oral Pathol (1975) 1.04
mTOR in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? J Clin Pathol (2008) 1.03
Review article: genetic testing and counselling for hereditary colorectal cancer. Aliment Pharmacol Ther (2002) 1.01
Analysis of masked mutations in familial adenomatous polyposis. Proc Natl Acad Sci U S A (1999) 1.01
Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol (2000) 1.00
Collagenous, "microscopic," lymphocytic, and other gentler and more subtle forms of colitis. Hum Pathol (1990) 1.00
Mucinous cystadenomas in liver: management and origin. Dig Surg (2010) 0.99
Genetic testing for cancer in children. Short-term psychological effect. Arch Pediatr Adolesc Med (1996) 0.98
Attitudes toward colon cancer gene testing: survey of relatives of colon cancer patients. Cancer Epidemiol Biomarkers Prev (1999) 0.97
Cystadenomas with ovarian stroma in liver and pancreas: an evolving concept. Dig Surg (2006) 0.97